RecruitingPhase 3NCT07266402

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Studying Familial cold urticaria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Celldex Therapeutics
Intervention
Barzolvolimab(drug)
Enrollment
240 target
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07266402 on ClinicalTrials.gov

Other trials for Familial cold urticaria

Additional recruiting or active studies for the same condition.

See all trials for Familial cold urticaria

← Back to all trials